Career history of Antony Blanc
Former positions of Antony Blanc
| Companies | Position | Start | End |
|---|---|---|---|
| CUREVAC N.V. | Corporate Officer/Principal | 2020-12-03 | 2023-11-30 |
| Mckinsey & Co., Inc. (Germany) | Corporate Officer/Principal | 2008-12-31 | 2016-12-31 |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Corporate Officer/Principal | 1999-12-31 | 2008-12-31 |
| SYNGENTA | Corporate Officer/Principal | 1999-12-31 | 2008-12-31 |
Training of Antony Blanc
| McGill University | Doctorate Degree |
Statistics
International
| Germany | 3 |
| Switzerland | 3 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Process Industries | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Private companies | 3 |
|---|---|
| Mckinsey & Co., Inc. (Germany) | |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Syngenta AG
 Syngenta AG Chemicals: AgriculturalProcess Industries Syngenta AG specializes in crop protection and seeds production. Its products include selective and non-selective herbicides, fungicides, insecticides, as well as field crop and vegetable seeds. The company was founded on November 12, 1999 and is headquartered in Basel, Switzerland. | Process Industries |
- Stock Market
- Insiders
- Antony Blanc
- Experience